v3.26.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Net revenue $ 1,070,280 $ 1,446,066 $ 3,932,386 $ 4,569,146
Operating expenses:        
Direct costs and expenses 1,114,176 942,211 3,130,649 3,326,673
Research and development 389,122 330,589 1,100,404 1,009,347
Clinical development 251,043 143,311 1,060,968 410,943
Selling, general and administrative 2,759,769 2,209,441 8,859,961 6,876,551
Depreciation and amortization 66,842 113,360 242,916 381,177
Total operating expenses 4,580,952 3,738,912 14,394,898 12,004,691
Loss from operations (3,510,672) (2,292,846) (10,462,512) (7,435,545)
Other income (expense):        
Interest income 4,734 1,088 18,118 3,655
Interest expense (10,713) (5,358) (37,123) (31,303)
Other income 3,144 513 6,516 38,568
Other expense (13,072) (3,839) (48,270) (16,828)
Offering costs allocated to warrant liability (532,209) (532,209) (479,696)
Loss on warrant liabilities (1,218,235) (2,747,460) (1,218,235) (3,810,278)
Total other income (expense), net (1,766,351) (2,755,056) (1,811,203) (4,295,882)
Net loss before provision for income tax expense (5,277,023) (5,047,902) (12,273,715) (11,731,427)
Income tax expense 3,182 40,861
Net loss $ (5,277,023) $ (5,051,084) $ (12,273,715) $ (11,772,288)
Net loss per common share, basic $ (5.89) $ (71.05) $ (23.72) $ (219.47)
Net loss per common share, diluted $ (5.89) $ (71.05) $ (23.72) $ (219.47)
Weighted average common shares outstanding, basic 896,271 71,090 517,490 53,640
Weighted average common shares outstanding, diluted 896,271 71,090 517,490 53,640

Source